SK Biopharm Announces Mid- to Long-Term Growth Strategy for Cenobamate

SK Biopharm has unveiled a mid- to long-term strategy aimed at expanding the treatment scope and sales regions for its epilepsy drug, Cenobamate, while securing growth momentum through new epilepsy drugs and next-generation cancer technologies.

SK Biopharm announced on November 18 that it presented this strategy during the Jefferies Global Healthcare Conference held in London from November 16 to 19 (local time). This event is the largest healthcare conference in Europe, gathering global pharmaceutical companies and institutional investors. SK Biopharm has attended for four consecutive years and is the only domestic pharmaceutical and biotech company to present on-site.

During the presentation on November 17, SK Biopharm CEO Lee Dong-hoon highlighted the achievements of Cenobamate. Known as 'Xcopri' in the United States, Cenobamate has surpassed 300,000 cumulative prescriptions worldwide as of September this year. The company is expanding the treatment range of Cenobamate, which was previously used for adult partial seizures, to include primary generalized tonic-clonic seizures and pediatric partial seizures for patients aged 12 and older. New formulations, such as oral suspensions, are also being developed for regulatory approval.

Sales regions are also expanding. Following commercialization in the United States, Europe, and the Middle East and North Africa (MENA), the company began sales in China in March this year and launched products in South Korea and Japan this month. In Latin America, products were introduced sequentially in Peru, Chile, and Brazil this year.

As a next growth driver, SK Biopharm is focusing on the epilepsy drug candidate 'Opacalim.' The company introduced Opacalim from Biohaven in the United States last August. It will be the second product utilizing the existing direct sales network in the U.S. Opacalim selectively activates potassium ion channels (Kv7.2/7.3) involved in the electrical signaling of nerve cells to suppress seizures. Clinical phase 2/3 trials are underway for adult partial seizure patients, with major results from the 'RISE3' trial expected in the second half of this year. Given that the patent for Cenobamate expires in 2032, Opacalim is anticipated to be a key product for maintaining revenue thereafter.

In the oncology field, the company is exploring new therapeutic targets centered on next-generation technologies such as radiopharmaceutical therapies (RPT) and targeted protein degradation (TPD). The CEO also introduced the 'AI Native Operation' strategy, which applies artificial intelligence (AI) to drug candidate discovery and operational management. Additionally, the 'East-West Bridge' strategy aims to identify promising candidates from Asian biotech firms and connect them to the global market.

Lee stated, "Based on the commercialization experience of Cenobamate in the U.S., we have entered a phase of expanding our growth areas and securing new growth drivers. We will actively utilize AI and open innovation to enhance the speed and competitiveness of drug development and strengthen the foundation for sustainable growth by expanding our business model that connects promising assets in Asia to the global market."

Meanwhile, SK Biopharm's epilepsy treatment Cenobamate has been launched in the Japanese market. This marks the establishment of a commercialization base in the three major Northeast Asian countries, following China and South Korea. Japan is estimated to be the second-largest epilepsy market in the world after the United States, with around 1 million patients.





* This article has been translated by AI.